This page shows the details of why an item matched the keywords from your search.
| Item Type | Name |
|
Concept
|
Receptor, Fibroblast Growth Factor, Type 1
|
|
Concept
|
Receptor, Fibroblast Growth Factor, Type 3
|
|
Concept
|
Receptor, Fibroblast Growth Factor, Type 2
|
|
Concept
|
Receptors, Fibroblast Growth Factor
|
|
Academic Article
|
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
|
|
Academic Article
|
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.
|
|
Academic Article
|
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.
|
|
Academic Article
|
First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.
|
|
Academic Article
|
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
|
|
Academic Article
|
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
|
|
Academic Article
|
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
|
|
Academic Article
|
Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
|
|
Academic Article
|
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.
|
- Fibroblast Growth Factor 7